INDOCO2024-01-012024-03-31 INDOCO2024-01-012024-03-31 INDOCO2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member INDOCO2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member INDOCO2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member INDOCO2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member INDOCO2024-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2023-04-01 2024-03-31 2024-05-16 2024-05-08 INR Lakhs Yearly 13:15:00 14:35:00 2024-05-16 2024-05-16 true Cash Flow Indirect Declaration of unmodified opinion Single segment PHARMACEUTICALS 2024-01-01 2024-03-31 Audited Standalone 4454900000.00 40500000.00 4495400000.00 1078800000.00 271700000.00 63800000.00 828700000.00 109100000.00 237300000.00 1638300000.00 4227700000.00 267700000.00 197300000.00 465000000.00 104600000.00 -15200000.00 89400000.00 0.00 375600000.00 0.00 0.00 0.00 0.00 375600000.00 7100000.00 382700000.00 0.00 0.00 184400000.00 2 4.08 4.07 0.00 0.00 4.08 4.07 0.00 0.00 0.00 1. The audited Standalone Results for the Quarter and Year ended 31st March, 2024 have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 16th May, 2024. The Statutory Auditors have expressed an Unmodified Audit opinion on these audited Standalone Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The Board of Directors have proposed, subject to the approval of shareholders in the ensuing Annual General Meeting a Dividend of 75 % i.e. Rs. 1.50 per equity share on face value of Rs. 2/-each to its equity shareholder's for the year 2023-2024. 4. During the quarter and year ended 31st March 2024, the Nomination and Remuneration Committee of the Board at its meeting held on 29th March, 2024 has approved the grant of 90,000 Employee Stock Options and 13,000 Restricted Stock Units to the eligible employees under Indoco Remedies Limited Employee Stock Option Plan- 2022. 5. In Nomination and Remuneration Committee Meeting held on 29th March 2024, the Company has allotted 31,850 number of equity shares to Indoco Employees Welfare Trust under Indoco Remedies Limited Employee Stock Option Plan- 2022. 6. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 7. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: (Rs. in lakhs) Net Sales ands Quarter ended Quarter ended Quarter ended Year ended Year ended Income from 31.03.2024 31.12.2023 31.03.2023 31.03.2024 31.03.2023 Operations Audited Unaudited Audited Audited Audited --------------------------------------------------------------------------------------------------------------------------- India 20816 23597 20228 92431 84787 Outside India 22698 21241 22577 83764 79026 Total 43514 44838 42805 176195 163813 ------------------------------------------------------------------------------------------------------------------------------ 8. Figures for the quarter ended 31.3.2024 and 31.3.2023 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2023 (limited reviewed) and 31.12.2022 (limited reviewed). 9. (*) Exceptional items include consideration received Rs. 19.7 cr for grants to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company. Single segment 2023-04-01 2024-03-31 Audited Standalone 17908100000.00 85100000.00 17993200000.00 4455000000.00 1156600000.00 -147000000.00 3505500000.00 368200000.00 879800000.00 6358200000.00 16576300000.00 1416900000.00 115300000.00 1532200000.00 327700000.00 38100000.00 365800000.00 0.00 1166400000.00 0.00 0.00 0.00 0.00 1166400000.00 400000.00 1166800000.00 0.00 0.00 184400000.00 2 11081800000.00 12.66 12.64 0.00 0.00 12.66 12.64 0.00 0.00 0.00 OTHER EXPENSES 1404900000.00 RESEARCH & DEVELOPMENT EXPENSE 233400000.00 OTHER EXPENSES 5386600000.00 RESEARCH & DEVELOPMENT EXPENSE 971600000.00 6353400000.00 925000000.00 0.00 969900000.00 219400000.00 0.00 0.00 519600000.00 908600000.00 64600000.00 1492800000.00 0.00 643400000.00 10603900000.00 3104200000.00 72400000.00 4080200000.00 74700000.00 94700000.00 14800000.00 267800000.00 4604600000.00 17400000.00 1276000000.00 9002200000.00 19606100000.00 184400000.00 11081800000.00 11266200000.00 11266200000.00 2160100000.00 49000000.00 2209100000.00 334700000.00 100000000.00 73600000.00 2717400000.00 2976500000.00 1189600000.00 835700000.00 5001800000.00 137900000.00 482800000.00 5622500000.00 8339900000.00 19606100000.00 365000000.00 155700000.00 -655100000.00 0.00 -142500000.00 -18400000.00 -52300000.00 -245600000.00 0.00 -74800000.00 0.00 -57500000.00 0.00 879800000.00 0.00 -11700000.00 1800000.00 254300000.00 71900000.00 5700000.00 0.00 60800000.00 26900000.00 0.00 0.00 0.00 80400000.00 3800000.00 0.00 526600000.00 2058800000.00 0.00 0.00 0.00 291000000.00 0.00 1767800000.00 0.00 330600000.00 0.00 62400000.00 0.00 0.00 0.00 0.00 16800000.00 1790300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 845700000.00 0.00 0.00 0.00 0.00 65900000.00 0.00 -70600000.00 0.00 -3016900000.00 0.00 0.00 7700000.00 0.00 0.00 0.00 0.00 0.00 1030000000.00 -790300000.00 38300000.00 0.00 207100000.00 358700000.00 0.00 0.00 1223900000.00 -25200000.00 0.00 -25200000.00 99900000.00 74700000.00 9500000.00 500000.00 2400000.00 100000.00 0.00 0.00